Market Cap: $138.33M
QC
Quanterix Corporation
QTRX
NASDAQ (NASDAQ Global Market)USD
Market Cap: $138.33M
Quanterix Advances Diagnostics with Innovative Biomarker Detection Technology Quanterix Corp. underscores its significant strides in biomarker detection technology as it announces its recent fourth-qu…
Quanterix Advances in Biomarker Detection Amid Strategic Growth Initiatives Quanterix, a frontrunner in the field of biomarker detection technology, records a notable surge in its fourth-quarter earni…
Quanterix Poised for Earnings Reveal: Focus on Innovation in Digital Immunoassays Quanterix, a leading innovator in the realm of digital immunoassays, prepares to announce its quarterly earnings on Ma…
Quanterix Gears Up for Earnings Announcement Amid Breakthroughs in Diagnostics Technology Quanterix, a leader in the field of digital immunoassays, prepares to announce its quarterly earnings on March…
Quanterix Advances in Biomarker Technology Amid Market Optimism Quanterix, a leader in digital immunoassay technology, is making significant strides in the field of biomarker discovery and diagnostics…
Quanterix Advances in Biomarker Technology Amid Market Optimism Quanterix Corporation, a leader in the field of digital immunoassay technology, continues to push the boundaries of biomarker measuremen…
Introduction: Quanterix Advances Diagnostic Precision Amid Earnings Season As companies across various sectors prepare to unveil their earnings, Quanterix, a leader in ultra-sensitive diagnostic testi…
Quanterix: Leveraging Advanced Diagnostics for Precision Medicine Quanterix, a leader in ultra-sensitive diagnostic testing, stands at the forefront of transforming healthcare through its innovative p…
Quanterix Poised for Earnings Report Amidst Innovations in Biomarker Technology Quanterix is on the brink of releasing its quarterly earnings report on November 10, 2025, an event that draws significa…
Quanterix Poised for Key Earnings Report Amidst Innovations in Biomarker Technology Quanterix (NASDAQ:QTRX) prepares to unveil its quarterly earnings report on November 10, 2025, a highly anticipated…
Quanterix Gears Up for Key Earnings Report Amid Industry Innovations As Quanterix (NASDAQ: QTRX) approaches its quarterly earnings report scheduled for November 10, 2025, the biotechnology company rem…
Quanterix Corporation: Pioneering Ultra-Sensitive Biomarker Detection Quanterix Corporation stands at the forefront of the biopharmaceutical industry, specializing in ultra-sensitive biomarker detecti…
Quanterix Focuses on Shareholder Rights Amid Corporate Developments Quanterix Corporation, a leader in digital biomarkers and advanced diagnostics, finds itself at the center of scrutiny as Halper Sad…
Quanterix Reports Strong Revenue Growth Amid Market Challenges Quanterix Corporation, a leader in advanced biomarker detection technology, announces its preliminary financial results for the fourth qu…
Quanterix and Akoya: Pioneering the Future of Biomarker Detection Quanterix Corporation, a leader in ultra-sensitive biomarker detection, announces a transformative merger with Akoya Biosciences, reno…
David R. Walt Receives National Medal of Technology and Innovation: A Testament to Quanterix’s Legacy Quanterix Corporation, a leader in digital immunoassay technology, recently celebrates a significa…
Innovative Recognition: Quanterix’s David R. Walt Awarded National Medal of Technology Quanterix Corporation, a leader in the field of advanced biomarker detection, celebrates a significant milestone…
Quanterix Sets the Stage for Innovation at the J.P. Morgan Healthcare Conference Quanterix Corporation, a pioneering entity in ultrasensitive biomarker detection, is poised to make a significant impac…
Quanterix Showcases Innovations in Biomarker Detection at Upcoming Healthcare Conference Quanterix Corporation, a leader in ultrasensitive biomarker detection based in Billerica, Massachusetts, prepar…
Quanterix Expands Technological Horizons with EMISSION Acquisition Quanterix Corporation, a prominent entity in ultrasensitive biomarker detection, announces its strategic acquisition of EMISSION Inc.…
Quanterix Faces Compliance Challenge Amid Financial Restatement Efforts Quanterix Corporation, a leader in high-sensitivity biomarker detection technology, receives a notification from The Nasdaq Stoc…
Quanterix Faces Legal Scrutiny Amid Financial Reporting Errors Quanterix Corporation, a leader in the field of precision health and diagnostics, finds itself under investigation from multiple law firm…
Quanterix Advances Alzheimer’s Diagnostics Amid Financial Adjustments Quanterix Corporation, a frontrunner in ultra-sensitive biomarker detection, announces notable progress in its Alzheimer’s disease…
Quanterix Prepares for Q3 2024 Financial Results Call Quanterix Corporation, a leader in ultrasensitive biomarker detection based in Billerica, Massachusetts, announces a forthcoming conference call s…
Revolutionizing Alzheimer’s Detection: LucentAD Complete Launches Quanterix Corporation’s brand, Lucent Diagnostics, introduces LucentAD Complete, an advanced multi-marker blood test designed to enhan…